StockStory.org on MSN
A look back at drug development inputs & services stocks’ Q4 earnings: Charles River Laboratories (NYSE:CRL) vs the rest of the pack
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Charles River Laboratories ...
Feb 18 (Reuters) - Contract drug developer Charles River Laboratories (CRL.N), opens new tab on Wednesday forecast annual profit above Wall Street estimates, betting on an improvement in demand for ...
T. Rowe Price Transitions to Charles River’s Enterprise Multi-Asset Investment Management Platform
BOSTON--(BUSINESS WIRE)-- Charles River Development, a State Street Company, announced today the expansion of its relationship with T. Rowe Price through the migration to the SaaS-deployed Charles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results